Recently published Complement Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
DelveInsight's 'Complement Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline complement inhibitors in various stages of clinical development, major ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
Iptacopan (Fabhalta) slowed kidney function decline in adults with immunoglobulin A (IgA) nephropathy, according to final data from the phase III APPLAUSE-IgAN study. The study met its primary ...
Although many things can affect your individual prognosis, about half of all patients will reach kidney failure within 10 years of their diagnosis and need dialysis or a kidney transplant. Even after ...
(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...
SAN DIEGO -- Intravenous ravulizumab (Ultomiris) yielded clinically meaningful reductions in IgA nephropathy-related proteinuria in a small, mid-stage trial. The 43 patients treated with ravulizumab ...
One of the most frustrating patterns in modern cancer treatment is that a therapy which works brilliantly at first can ...
The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...
Paroxysmal nocturnal hemoglobinuria has long been one of hematology’s cruelest puzzles: a rare, acquired stem-cell mutation that leaves red blood cells defenseless against the body’s own com ...
A webcast of the panel discussion will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results